Abstract:Background To explore the pharmacodynamic evaluation and mechanism research of BOC26P against breast cancer, and to provide a basis for the treatment of breast cancer. Method MTT assay was used to detect the cytotoxicity of BOC26P against 4 breast cancer cell lines (MCF-7/TAX, MDA-MB-231/PT, MDA-MB-231and MCF-7), and as well as the non-tumor cell lines MCF-10A, in various drug concentrations (from 0.004 to 1uM). Western Blotting and Real-Time PCR assay were used to detect the relative protein and gene expression level after treatment with BOC26P in MCF-7/TAX. The effect of BOC26P on Specific fluorescent P-gp substrate accumulation in MCF-7/TAX was analyzed by flow cytometry; Molecular docking was used to analyze the binding capacity between BOC26P, Cyclosporine A, and Verapamil. FCM assay staining with Annexin V-FITC/PI and Propidium iodide was used to measure the apoptosis and the cell cycle after treatment with BOC26P in MCF-7/TAX, MDA-MB-231/PT, MDA-MB-231, and MCF-7; Detection of mitochondrial membrane potential after treatment with BOC26P inMCF-7/TAX, MDA-MB-231/PT, MDA-MB-231and MCF-7; Western Blotting and Real-Time PCR assay was used to detect the apoptosis relative protein and gene expression level after treatment with BOC26P in MDA-MB-231, MCF-7, MDA-MB-231/PT, and MCF-7/ADR. Results Cytotoxicity assay showed that BOC26P could effectively suppress 4 breast cancer cell lines (MCF-7/TAX, MDA-MB-231/PT, MDA-MB-231, and MCF-7) with an IC50 value of under 0.5 ?M. The IC50 value of BOC26P on non-tumor cells MCF-10A was 32.29 uM. The binding ability of BOC26P to P-gp in breast cancer cells was weak. There was no significant effect on the intracellular accumulation of Rhodamin 123(Rh123), P-gp binding specific fluorescence substrate, and multi-drug resistance protein P-gp expression in MCF-7/ADR and MDA-MB-231/PT tumor cells; BOC26P induced MCF-7/TAX, MDA-MB-231/PT, MDA-MB-231 and MCF-7 cells cycle arrest at G2/M phase and lead to cell apoptosis. BOC26P induced significant activation of p53 protein in MCF-7/ADR and MAD-MB-231/TAX cells. Under the same conditions, BOC26P promoted Bax expression while inhibited Bcl-2 expression, and could significantly cause activation of Cleveland PARP and Clevead Caspase3. The results demonstrated that BOC26P may induce apoptosis through the death receptor apoptosis pathway. Conclusion It is known that BOC26P has a significant proliferation inhibitory effect on breast cancer cells without serious side effects. BOC26P has the Potential to be developed into a clinical substitute drug for triple-negative breast cancer and drug- resistance breast cancer. BOC26P, a cytotoxic antitumor candidate compound but not a P-gp substrate, does not interfere with P-gp expression and efflux function in the P-gp-positive drug-resistant breast cancer cells, that is, it can avoid P-gp mediated multidrug resistance pathway in breast cancer. BOC26P activates the membrane stability protein Bcl-2 family in MDA-MB-231/PT, MCF-7/ADR and MA-MB-231 mitochondrial pathways of drug-resistant human breast cancer cells and their maternally sensitive cells, causing mitochondrial rupture, releasing P53, and activating the caspase-mediated apoptosis pathway, thus causing apoptosis of breast cancer cells. The significant inhibitory activity of BOC26P on breast cancer resistant cells may be related to P53, Activation of P53 and other tumor suppressor genes alters the expression of Bcl-2 and Bax, further activates the Caspase cascade initiates apoptosis pathway, and cause apoptosis eventually.

A Novel 3-Acyl Isoquinolin-1(2H)-one Induces G2 Phase Arrest, Apoptosis and GSDME-dependent Pyroptosis in Breast Cancer

Anti-proliferative and Apoptotic Effects of S1, a Tetrandrine Derivative, in Human Gastric Cancer BGC-823 Cells

N-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide Induces Apoptosis in Human Breast Cancer Cells by Stimulating Oxidative Stress and Inhibiting the Notch-Akt Signaling Pathway

A Novel Inhibitor of Poly( ADP - R ibose) Polymerase-1 Inhibits Proliferation of a BRCA-Deficient Breast Cancer Cell Line via the DNA D amage– A ctivated cGAS–STING Pathway

Pyrrolo [3,4-B]-quinolin-9-amine Compound FZU-0038-056 Suppresses Triple-Negative Breast Cancer Partially Through Inhibiting the Expression of Bcl-2

Design, Synthesis and Biological Evaluation of Pyrimidine Derivatives As Novel CDK2 Inhibitors That Induce Apoptosis and Cell Cycle Arrest in Breast Cancer Cells.

Novel camphor-based pyrimidine derivatives induced cancer cell death through a ROS-mediated mitochondrial apoptosis pathway

A New Protoapigenone Analog RY10-4 Induces Apoptosis and Suppresses Invasion Through the PI3K/Akt Pathway in Human Breast Cancer.

An autophagy-dependent cell death of MDA-MB-231 cells triggered by a novel Rhein derivative 4F.

KU004 induces G1 cell cycle arrest in human breast cancer SKBR-3 cells by modulating PI3K/Akt pathway

Studies on the Anti-Proliferative Effects and Molecular Mechanism of a Novel Small Molecular BOC26P in Breast Cancer

Design and discovery of novel pyrazole‐pyrrolopyrimidine derivatives as anti‐glioma agents via promoting apoptosis, inhibiting cell cycle and EGFR‐TK

#2714, a Novel Active Inhibitor with Potent G2/M Phase Arrest and Antitumor Efficacy in Preclinical Models

Design, synthesis and biological assessment of novel CDK4 inhibitor with potent anticancer activity

A novel protoapigenone analog RY10-4 induces apoptosis of breast cancer cells by regulating mitochondrial Ca2+ influx through the mitochondrial calcium uniporter

A Novel Cinnamide Ylt26 Induces Breast Cancer Cells Apoptosis Via Ros-Mitochondrial Apoptotic Pathway In Vitro And Inhibits Lung Metastasis In Vivo

Structurally diverse design and synthesis of novel 2-phenylindole amide derivatives with anti-canine breast cancer activity

Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells

Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents.

Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer

Design, synthesis and in vitro anticancer research of novel tetrandrine and fangchinoline derivatives